Clinical Trials Browser

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT03312530 2023-02-28

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

49 enrolled 24 charts

Plasma cell

Multiple Myeloma

NCT02639546 2022-09-16

iMATRIXcobi

Phase 1/2 Completed

56 enrolled 31 charts

Other solid neoplasm

Solid Tumors

NCT01959633 2022-02-24

VEMUPLINT

Phase 1/2 Completed

11 enrolled

Dermatologic

Melanoma

NCT03566485 2021-08-11

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Breast

Breast Neoplasms

Clinical Trials

Morpheus Lung

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

COTESARC

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

MyDRUG

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

MEKiAUTO

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

iMATRIXcobi

VEMUPLINT

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer